Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.
Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Vandemeulebroucke E, et al. Diabetologia. 2010 Jan;53(1):36-44. doi: 10.1007/s00125-009-1569-3. Epub 2009 Nov 7. Diabetologia. 2010. PMID: 19898832 Free article.
HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.
Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry. Mbunwe E, et al. Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16. Diabetes. 2013. PMID: 23160529 Free PMC article.
In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.
Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Mbunwe E, et al. Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28. Diabetologia. 2013. PMID: 23712485 Free PMC article.
The relationship between changes in steps/day and health outcomes after a pedometer-based physical activity intervention with telephone support in type 2 diabetes patients.
Van Dyck D, De Greef K, Deforche B, Ruige J, Bouckaert J, Tudor-Locke CE, Kaufman JM, De Bourdeaudhuij I. Van Dyck D, et al. Among authors: ruige j. Health Educ Res. 2013 Jun;28(3):539-45. doi: 10.1093/her/cyt038. Epub 2013 Mar 14. Health Educ Res. 2013. PMID: 23492248 Clinical Trial.
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators. Dandona P, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Lancet Diabetes Endocrinol. 2017. PMID: 28919061 Clinical Trial.
64 results